TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01048268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose-dependent insulinotropic polypeptide
Description: For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose-dependent insulinotropic polypeptide
Description: For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose-dependent insulinotropic polypeptide
Description: For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: copy GIP infusion rates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: copy GIP infusion rates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: copy GIP infusion rates
Study: NCT02577900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acticoat absorbent
Description: Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Honey gel sheet
Description: Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval

Intervention type: DEVICE
Group type: OTHER
Intervention: Jelonet
Description: Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
Study: NCT05117866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel Monotherapy
Description: Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
Study: NCT04542330

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark
Description: Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
Study: NCT04580472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
Study: NCT04058600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Software
Description: Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
Study: NCT03599843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
Study: NCT01682512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera®
Study: NCT04583631

Intervention type: PROCEDURE
Intervention: Adenoidectomy surgery
Description: All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.

Intervention type: PROCEDURE
Intervention: Adenoidectomy surgery
Description: All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
Study: NCT04181216

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomically aligned total knee arthroplasty implant
Description: In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically aligned total knee arthroplasty implant
Description: In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
Study: NCT01578343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
Description: 1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation
Study: NCT02203188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lid debridgement scaling
Study: NCT06545448

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention (PCI)
Description: A percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked coronary (heart) arteries. An older name for PCI is coronary angioplasty with stenting or angioplasty for short.
Study: NCT04643054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ovotransferrin
Description: Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
Study: NCT02505165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: • The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.

Intervention type: OTHER
Group type: OTHER
Intervention: ESO
Description: This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
Study: NCT02989610

Intervention type: DEVICE
Intervention: Omnidirectional stimulation
Description: At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.

Intervention type: DEVICE
Intervention: Directional stimulation
Description: At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
Study: NCT04179474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: 2 SC injections of galcanezumab 120 mg \[Intervention C\].
Study: NCT03934437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mLTCR
Description: mHealth-enhanced Linkage to Care and Retention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LTCR
Description: Linkage and Retention Services (Standard-of-Care)
Study: NCT01083901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: high intensity progressive resistance exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: high intensity progressive resistance exercise training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: high intensity progressive resistance exercise training
Study: NCT04554927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WEB-Application
Description: The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard accompaniment
Description: Personalized schedule of medical follow-up given to the patient
Study: NCT03945760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib 2 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04339361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine spray
Description: four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal dinoprostone
Description: vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study: NCT00377715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02224300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based education of venous leg ulcer nursing care
Description: Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
Study: NCT02702271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX
Description: Left atrial appendage closure with WATCHMAN FLX

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX
Description: Left atrial appendage closure with WATCHMAN FLX
Study: NCT02933827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIXCYTE
Description: Adipose-derived stem cells (ADSCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIXCYTE
Description: Adipose-derived stem cells (ADSCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIXCYTE
Description: Adipose-derived stem cells (ADSCs)
Study: NCT00858559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator with Home Monitoring function
Description: Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard implantable cardioverter defibrillator
Description: Implantable cardioverter defibrillators used as standard devices without Home Monitoring
Study: NCT02632383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Young with Diabetes - app
Description: The mHealth app Young with Diabetes containes 8 main functions:~1. Contact your health care provider (ask questions, set the agenda for the next clinical visit)~2. My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~3. Chatroom~4. Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~5. Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~6. Tips packages (Receive a tip about alcohol, drivers license etc.)~7. To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~8. Reminder
Study: NCT01506817

Intervention type: PROCEDURE
Intervention: Dynamic contrast-enhanced MRI of the hands
Description: The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.

Intervention type: PROCEDURE
Intervention: Dynamic contrast-enhanced MRI of the hands
Description: The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
Study: NCT00540007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT00854607

Intervention type: OTHER
Intervention: No Intervention
Description: Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
Study: NCT03706274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-188
Description: CX-188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-188
Description: CX-188
Study: NCT03205007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion nutrition program
Description: Health promotion nutrition program
Study: NCT03903952

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin B12 and folate
Description: Vitamin B12 and folate levels in blood

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin B12 and folate
Description: Vitamin B12 and folate levels in blood
Study: NCT02399059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antibiotic lavage
Description: Peritoneal irrigation with gentamycin-clindamycin solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline lavage
Description: Peritoneal irrigation with normal saline
Study: NCT01254994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional comprehensive medical treatment
Description: bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
Study: NCT01042002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: High intensity exercise 3xweek for minimum 6 weeks
Study: NCT04253756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20-gauge BD Nexiva Diffusics
Description: The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
Study: NCT00091507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK
Description: Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
Study: NCT03888573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching protocol
Description: Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching protocol
Description: Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
Study: NCT03807362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11050
Description: CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
Study: NCT00741234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: SB939 taken orally in a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: SB939 taken orally in a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: SB939 taken orally in a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine taken orally with SB939 in a 4-week cycle
Study: NCT01579123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty
Description: With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser atherectomy
Description: Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
Study: NCT02009176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Anatomical Hepatectomy
Description: We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
Study: NCT04118855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg by mouth twice each day for 12 weeks prior to nephrectomy
Study: NCT02177864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (low fiber bar)
Study: NCT03996980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses Versus a flat insole
Description: Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Custom-made foot orthoses Versus a flat insole
Description: Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)